In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 3, 2012, Pages 272-277

  Krishnan Natesan, S ^a   Wu, Wenjuan ^b   Cutright, J L ^b   Chandrasekar, P H ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Aspergillus; Cyp51A; G448S mutation; Murine; Posaconazole; Voriconazole resistance

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CYP51A GENE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS MUTANT; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PATHOGEN LOAD; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; HUMANS; MICE; MICE, INBRED ICR; MUTATION, MISSENSE; PULMONARY ASPERGILLOSIS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84867640634     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.06.030     Document Type: Article

References (50)

1. Allendoerfer R., Loebenberg D., Rinaldi M.G., Graybill J.R. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995, 39:1345-1348.
2. Beernaert L.A., Pasmans F., Van Waeyenberghe L., Dorrestein G.M., Verstappen F., Vercammen F., et al. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole. Antimicrob Agents Chemother 2009, 53:2199-2201.
3. Bellete B., Raberin H., Morel J., Flori P., Hafid J., Manhsung R.T. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol 2010, 48:197-200.
4. Bowyer P., Moore C.B., Rautemaa R., Denning D.W., Richardson M.D. Azole antifungal resistance today: focus on Aspergillus. Curr Infect Dis Rep 2011, 13:485-491.
5. Burgel P.R., Baixench M.T., Amsellem M., Audureau E., Chapron J., Kanaan R., et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2011, 56(2):869-874.
6. Camps S.M., van der Linden J.W., Li Y., Kuijper E.J., van Dissel J.T., Verweij P.E., et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012, 56:10-16.
7. Chowdhary A., Kathuria S., Randhawa H.S., Gaur S.N., Klaassen C.H., Meis J.F. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2011, 67(2):362-366.
8. Denning D.W., Perlin D.S. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol 2011, 6(11):1229-1232.
9. Denning D.W., Park S., Lass-Florl C., Fraczek M.G., Kirwan M., Gore R., et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011, 52:1123-1129.
10. Escribano P., Recio S., Peláez T., González-Rivera M., Bouza E., Guinea J. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob Agents Chemother 2012, 56:174-178.
11. Farowski F., Vehreschild J.J., Cornely O.A. Posaconazole: a next-generation triazole antifungal. Future Microbiol 2007, 2:231-243.
12. Frampton J.E., Scott L.J. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs 2008, 68:993-1016.
13. Graybill J.R., Bocanegra R., Najvar L.K., Luther M.F., Loebenberg D. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998, 42:539-542.
14. Graybill J.R., Najvar L.K., Gonzalez G.M., Hernandez S., Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 2003, 51:1373-1376.
15. Groll A.H., Walsh T.J. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006, 49(Suppl. 1):7-16.
16. He Z.M., Price M.S., Obrian G.R., Georgianna D.R., Payne G.A. Improved protocols for functional analysis in the pathogenic fungus Aspergillus flavus. BMC Microbiol 2007, 7:104.
17. Hodiamont C.J., Dolman K.M., Ten Berge I.J., Melchers W.J., Verweij P.E., Pajkrt D. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 2009, 47:217-220.
18. Hector R.F., Yee E., Collins M.S. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 1990, 58:1476-1478.
19. Howard S.J., Webster I., Moore C.B., Gardiner R.E., Park S., Perlin D.S., et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006, 28:450-453.
20. Howard S.J., Pasqualotto A.C., Denning D.W. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2009, 16:683-686.
21. Imai J.K., Singh G., Clemons K.V., Stevens D.A. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004, 48:4063-4066.
22. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
23. Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Loebenberg D., Rinaldi M.G., Patterson T.F. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000, 44:780-782.
24. Klaassen C.H., de Valk H.A., Curfs-Breuker I.M., Meis J.F. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother 2010, 65:901-905.
25. Manavathu E.K., Baskaran I., Krishnan S., Alangaden G., Chandrasekar P.H. Cytochrome P450 14-sterol demethylase mutation dependent triazole cross resistance in Aspergillus fumigatus. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2003, M-471.
26. Manavathu E., Espinel-Ingroff A., Alangaden G., Chandrasekar P.H. Molecular studies on voriconazole-resistance in a clinical isolate of Aspergillus fumigatus 2003, M-392.
27. Mavridou E., Brüggemann R.J., Melchers W.J., Mouton J.W., Verweij P.E. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010, 54:860-865.
28. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Cuenca-Estrella M., Rodriguez-Tudela J.L. Substitutions at methionine 220 in the 14alpha-sterol demethylase (cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004, 48:2747-2750.
29. Mellado E., Garcia-Effron G., Alcázar-Fuoli L., Melchers W.J., Verweij P.E., Cuenca-Estrella M., et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007, 51:1897-1904.
30. Meneau I., Sanglard D. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 2005, 43(Suppl. 1):S307-S311.
31. Mosquera J., Denning D.W. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002, 46:556-557.
32. Munayyer H.K., Mann P.A., Chau A.S., Yarosh-Tomaine T., Greene J.R., Hare R.S., et al. Posaconazole is a potent inhibitor of sterol 14-alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004, 48:3690-3696.
33. Nascimento A.M., Goldman G.H., Park S., Marras S.A., Delmas G., Oza U., et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 2003, 47:1719-1726.
34. Notheis G., Tarani L., Costantino F., Jansson A., Rosenecker J., Friederici D., et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006, 49(Suppl. 1):37-41.
35. Oakley K.L., Morrissey G., Denning D.W. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997, 41:1504-1507.
36. Pelaez T., Gijón P., Bunsow E., Bouza E., Sánchez-Yebra W., Valerio M., et al. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. J Clin Microbiol 2012, 50(7):2531-2534.
37. Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012, 125(1 Suppl.):S3-13.
38. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008, 46:2568-2572.
39. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Monzon A., Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008, 52(7):2468-2472.
40. Snelders E., van der Lee H.A., Kuijpers J., Rijs A.J., Varga J., Samson R.A., et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008, 5:e219.
41. Snelders E., Huis In't Veld R.A., Rijs A.J., Kema G.H., Melchers W.J., Verweij P.E. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009, 75:4053-4057.
42. Szewczyk E., Nayak T., Oakley C.E., Edgerton H., Xiong Y., Taheri-Talesh N., et al. Fusion PCR and gene targeting in Aspergillus nidulans. Nat Protoc 2006, 1:3111-3120.
43. Tashiro M., Izumikawa K., Minematsu A., Hirano K., Iwanaga N., Ide S., et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 2012, 56:584-587.
44. Thors V.S., Bierings M.B., Melchers W.J., Verweij P.E., Wolfs T.F. Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy. Pediatr Infect Dis J 2011, 30:268-270.
45. Torres H.A., Hachem R.Y., Chemaly R.F., Kontoyiannis D.P., Raad I.I. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005, 5:775-785.
46. van der Linden J.W., Snelders E., Kampinga G.A., Rijnders B.J., Mattsson E., Debets-Ossenkopp Y.J., et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011, 17:1846-1854.
47. Verweij P.E., Mellado E., Melchers W.J. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 356:1481-1483.
48. Verweij P.E., Snelders E., Kema G.H. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis 2009, 9:789-795.
49. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12.
50. Xiao L., Madison V., Chau A.S., Loebenberg D., Palermo R.E., McNicholas P.M. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004, 48:568-574.